• BAUHUB
  • BAU Alumni
  • BAU Global
  • Communication & Transportation
  • COOP
TR SAP Giriş APPLY BAU PROSPECTIVE STUDENT

BAU | Bahçeşehir Üniversitesi

BAU | Bahçeşehir Üniversitesi BAU | Bahçeşehir Üniversitesi
TR SAP Giriş
  • About BAU
    • About the University
      • Bahcesehir University
      • Message From The Chair Of The Board Of Trustees
      • President's Message
      • History
      • Bahçeşehir in Numbers
      • Vision & Mission
      • Sports at BAU
      • Clinical Research Ethics Board
      • Principles and Policies
      • Quality Assurance System
    • Management
      • Board of Trustees
      • Academic Administration
      • Management Board
      • Senate
      • Rectorate
      • General Secretariat
    • BAU Global Education Network (Gallery)
      • Beşiktaş South Campus
      • Beşiktaş North Campus
      • Galata Campus
      • Göztepe Campus
      • Future Campus
      • Pera Campus
      • Çatalca Campus
      • BAU Global Washington DC
      • BAU Global Berlin
      • BAU Global Batumi
      • BAU Global Cyprus
      • BAU Global Plymouth
      • Mentora Collage
    • Media
      • Photo Gallery
      • Video Gallery
      • Press Room
  • Academic Life
    • Schools
      • School of Foreign Languages
      • Vocational School
      • Vocational School of Health Services
      • School of Applied Disciplines
    • Faculties and Departments
      • Faculty of Dentistry
      • Faculty of Pharmacy
      • Faculty of Educational Sciences
      • Faculty of Law
      • Faculty of Communication
      • Faculty of Economics, Adminstrative and Social Sciences
      • Faculty of Architecture and Design
      • Conservatory
      • Faculty of Engineering and Natural Sciences
      • Faculty of Health Sciences
      • Faculty of Medicine
    • MA and PhD
      • Graduate School of Education
      • Education Sciences Graduate Programs
      • Law Graduate Programs
      • Communication Graduate Programs
      • Business Graduate Programs
      • Engineering Graduate Programs
      • Health Graduate Programs
      • Art and Design Graduate Programs
      • Social Sciences Graduate Programs
      • Global Politics and International Relations Graduate Programs
    • Research Center
      • Research and Applications Centers
      • International Academic Relations
  • Research
  • International Offices
    • International Students
      • International Students
    • Erasmus & Exchange Students
      • Erasmus & Exchange Students
  • Student
  • Home
  • /
  • Drug Study Continues for Covid 19
  • News
    • All News

Drug Study Continues for Covid 19

Drug studies determined by drug repositioning against COVID-19 within the TUBITAK COVID-19 Turkey Platform and led by Serdar Durdağı continues at full speed.

As a part of TÜBİTAK COVID-19 Turkey Platform, The COVID-19 Phase-2 clinical studies of Montelukast conducted by the head of Bahçeşehir University (BAU) Faculty of Medicine, Basic Medical Sciences and the Biophysics Department Prof. Dr. Serdar Durdağı, continues.

In the project carried out jointly by BAU and Istanbul Medipol University, the effectiveness of the drug Montelukast, which is used in the treatment of asthma and allergies, against COVID-19 is being investigated on volunteer patients in 5 different centers.

“BLOCKS THE VIRUS TO ENTER THE CELL AND REPRODUCE”

It was emphasized that the drug called "Montelukast” used in the treatment of asthma and allergy in the project, also has a strong effect in the treatment of COVID-19 in preclinical tests, and the drug delays the effect of the virus on healthy cells for up to 20 hours. After the vaccine studies, the molecule that blocks the virüs to enter the cell and reproduce also gives hope for drug studies too. Phase-2 clinic studies that started last month and planned to conduct on 380 volunteer patients, continue in 5 different headquarters in Istanbul, Ankara, and Samsun. It is expected that the number of headquarters where clinical studies are carried out will be increased to 9 in the upcoming days.

Explaining that among the library of 15 thousand molecules created from approved drugs used in the treatment of different diseases and drugs used in clinical phase stages, biochemical tests were performed on 25 molecules selected with virtual scanning algorithms developed in BAU Computational Biology and Molecular Simulations Laboratory. Dr. Serdar Durdağı said that in the virus neutralization tests performed at TÜBİTAK MAM, Montelukast was effective according to the preclinical test results. Prof. Dr. Serdar Durdağı explained that the biochemical tests were performed on 25 molecules, which were selected by virtual scanning algorithms created in BAU Computational Biology and Molecular Dynamics Laboratories chose among 15 thousand molecules created from certified drugs that are used in the treatment of different diseases and clinic phase stages. He said that in the virus neutralization tests performed at TÜBİTAK MAM, Montelukast was effective as to preclinical test results. Durdağı emphasized that the previous simulations showed that the drug was effective against the UK and South African variants and that Montelukast has the potential to be effective against the delta variant in the new simulations.

 

BAU | Bahçeşehir Üniversitesi BAU | Bahçeşehir Üniversitesi
  • ABOUT BAU
  • ADMINISTRATIVE UNITS
  • BAU E-POSTA
  • ACADEMIC CALENDAR
  • CONTACT US
  • TUITION AND SCHOLARSHIP
Ask Türkiye
BAU Global
Make Impact
Unitar
BAU | Bahçeşehir Üniversitesi

© 2020 Bahçeşehir Üniversitesi - Tüm Hakları Saklıdır.

Program and Design by CETEKNO

BAU | Bahçeşehir Üniversitesi BAU | Bahçeşehir Üniversitesi

© 2021 Bahçeşehir Üniversitesi - All rights reserved.